DOCSLIB.ORG

Comments on Tobacco Products; Required Warnings for Cigarette

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comments on Tobacco Products; Required Warnings for Cigarette EXECUTIVE SUMMARY Government-mandated health warnings have been required to appear on cigarette packages for more than 50 years and on cigarette advertisements for more than 45 years. Today, cigarette smoking is at an all-time low. PM USA and Nat Sherman believe that adult smokers should have the right to make informed choices about the use of tobacco products and that there should be a single, consistent public health message about the risks of smoking that should help guide these choices. While we recognize the need for health warnings on cigarette packages and advertisements, FDA’s second attempt at a regulation requiring graphic health warnings suffers from a number of fatal flaws. Our comments are organized into four sections. The first section urges FDA to exempt HeatSticks®, which are unique non-combustible “cigarettes” designed for use with the IQOS® tobacco heating system, from this rule. Although those products do not eliminate all health risks associated with tobacco and nicotine use, they are materially different from traditional combustible cigarettes, and, we believe, also significantly less harmful. Indeed, this Agency has already determined that the marketing of this product is “appropriate for the protection of public health.” The second section raises practical concerns impacting the implementation of the Proposed Rule. The third section explains that without substantial changes, the Proposed Rule would violate the Administrative Procedure Act (“APA”) on multiple grounds. The fourth, and final, section demonstrates that the text and graphic warnings proposed by this rule would violate free speech protections guaranteed by the First Amendment of the U.S. Constitution. To guide the Agency in the materials that follow, we provide an overview of the four sections listed above. Any Final Rule Should Exempt HeatSticks® from the Proposed Graphic-Warnings Requirements IQOS® is an electronic device that heats tobacco in HeatSticks® to generate nicotine-containing aerosol without combustion, fire, ash, or smoke. After a thorough science-based review, FDA granted marketing authorization for IQOS® and HeatSticks® in April 2019, concluding that marketing those products would be “appropriate for the protection of public health.”1 FDA based this conclusion on its rigorous assessment of the critical differences between HeatSticks® and traditional, combustible cigarettes. FDA noted several material differences—among them, that HeatSticks® do not combust or produce smoke; that HeatSticks® reduce exposures to harmful and potentially harmful constituents (“HPHCs”); that HeatSticks® are “likely to lead to less risk of tobacco-related diseases;” and that HeatSticks® have the potential to benefit current smokers who switch to them.2 Because HeatSticks® qualify as a “cigarette” as that term is defined in the Federal Cigarette Labeling and Advertising Act (“FCLAA”),3 FDA’s Marketing Order requires HeatSticks® packaging and advertising to bear the rotating Surgeon General’s warnings required by that Act. Significantly, however, based on the Agency’s recognition of significant differences 1 Attachment 1, CTP Technical Project Lead Review (TPL) Review of IQOS PMTA: PM0000424, PM0000425, PM0000426, and PM0000479 (April 29, 2019) (“IQOS® TPL Review”) at 12, available at https://www.fda.gov/media/124247/download. 2 Id. at 11-12, 92, 95; see also id. at 64-65. 3 15 U.S.C. § 1332(1). 2 between HeatSticks® and traditional combustible cigarettes, FDA also changed the mandated textual warnings that accompany HeatSticks®, for instance by excluding the Surgeon General’s carbon monoxide warning.4 Although IQOS® and HeatSticks® do not eliminate all health risks associated with tobacco and nicotine use, we believe they are significantly less harmful than traditional, combustible cigarettes, and FDA has determined that the marketing of this unique form of “cigarette” is “appropriate for the protection of public health.” Notwithstanding the differences between HeatSticks® and combustible cigarettes, the Proposed Rule would apply the graphic-warnings requirements to HeatSticks® even though those graphic warnings would not educate consumers about the health risks of using HeatSticks®. To the contrary, those warnings would misinform consumers by suggesting, inaccurately and without evidence, that HeatSticks® have the exact same health risks as traditional combustible cigarettes, and by describing HeatSticks® as involving “smoking” or “tobacco smoke.” Imposing the graphic-warnings requirements on HeatSticks®, in short, would undermine FDA’s stated policy goal of promoting greater public understanding of the negative health consequences of cigarette smoking. It would also frustrate FDA’s strategy of adopting policies to move smokers to non-combusted tobacco products lower on the continuum of risk. And, in addition to undermining important health policy objectives, imposing the graphic-warnings requirements on HeatSticks® would violate the APA and the U.S. Constitution on multiple grounds. For these reasons, we respectfully urge FDA to exempt HeatSticks® from the scope of any final rule. The Proposed Rule Raises Practical Concerns Impacting the Implementation of the Required Warnings on Cigarette Packages and Advertisements The Proposed Rule, if finalized in its current form, would create significant implementation problems for both regulated industry and FDA that would substantially hinder the ability of the regulated industry to comply with the requirements of the rule. FDA should modify the Proposed Rule to address each of these problems. First, as an initial matter, FDA should reduce the number of required graphic warnings from 13 to either 12 or 9. This modification is necessary due to extremely difficult and potentially insurmountable technical challenges with printing and distributing 13 warnings equally and randomly on cigarette packages. Second, FDA should address other issues, addressed in more detail below, impacting the implementation of the required warnings on cigarette packages to provide flexibility to manufacturers and to account for the variety of cigarette package shapes and sizes in the marketplace. Third, FDA should address issues impacting the implementation of the required warnings on cigarette advertisements. These issues include the need for FDA to account for and provide clear direction regarding different formats and sizes. 4 See Attachment 2, Philip Morris Products S.A. Marketing Order, FDA Submission Tracking Numbers (STNs): PM0000424-PM0000426, PM0000479 (April 30, 2019) (“FDA Marketing Order”) at 13 n.9, available at https://www.fda.gov/media/124248/download. 3 Finally, FDA should extend or toll the implementation deadline to account for the complex and interdependent chain of events necessary for manufacturers to implement graphic health warnings. The Proposed Rule, if Finalized Without Substantial Changes, Would Violate the Administrative Procedure Act The Proposed Rule, if adopted without substantial modifications, would violate the APA. Agency action, findings, and conclusions must be set aside where they exceed the Agency’s authority, fail to comply with statutory requirements, or are “arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.”5 The Proposed Rule cannot survive scrutiny under these standards. First, FDA failed to disclose sufficient information about referenced research studies to allow for meaningful evaluation of their validity, in violation of both the Family Smoking Prevention and Tobacco Control Act (“TCA”) and general principles of administrative law. Nor has FDA provided sufficient information for stakeholders to determine why it highlighted certain diseases over others in the graphic warnings; why it selected the particular graphics it chose; or how or why it determined that the proposed warning statements are comprehensible to consumers. Second, FDA relies upon unreliable evidence that does not adequately support the Proposed Rule. FDA’s core evidence consists of commissioned studies that are seriously flawed in their design. FDA’s other cited studies fare no better, relying on data from non-U.S. populations without justification and in disregard of FDA’s own scientific standards, and suffering from various methodological defects. Individually, and even more so collectively, these flaws call into question the reliability and soundness of FDA’s primary scientific justifications for the Proposed Rule. Third, even if FDA’s studies were reliable, their results do not support FDA’s conclusion that the proposed graphic warnings would be effective in improving public understanding of the health consequences of smoking. FDA’s own commissioned studies are the only scientific evidence invoked by the Proposed Rule that even purport to test the replicability of the actual proposed warnings. And their results do not support the Proposed Rule. Fourth, in violation of the APA, FDA does not adequately address science and evidence that runs contrary to its proposal. FDA either ignores or fails to adequately explain a litany of evidence that undermines virtually every premise of the Proposed Rule. This includes: (i) evidence that graphic warnings do not meaningfully influence consumer knowledge regarding the consequences of smoking; (ii) evidence that graphic warnings may backfire, prompting consumers to avoid or reject them in fear or disgust; (iii) evidence that the proposed size requirements for packaging and advertisements do not advance consumer understanding; (iv) evidence
Load more

Recommended publications
  • “They Twisted My Arm to Get These Deals.”
    03-04_TAA_catalog.cg3 7/1/03 12:35 PM Page 1 2003/2004 2003 PIPE OF THE YEAR Erik says: AT PRICES “They twisted my arm “YOU WILL NEVER SEE AGAIN!” to get these deals.” SEE PAGE 2 03-04_TAA_catalog.cg3 7/1/03 12:35 PM Page 2 “They twisted my arm to get these No two handmade pipes The best value deals, you can’t beat these prices!” are exactly alike. on the market! EXCLUSIVE Bjarne Nielsen offers an The famous Danish pipe maker, Erik Nording, excellent pipe at a fair price. presents OCASO pipes at prices you His reputation depends on it. will never see again! Bjarne churchwarden pipes 3C 2003 Pipe of the Year are the latest rage, but all of these shapes are exquisite. 3D* 2B 3E 2C * 3F 2A 2A Nording Freehand Tall, smooth. 2C Nording Freehand Apple, with carving. 3G* Normally $200. Now only $110.00 Normally $100. Now only $59.95 2B Nording Freehand Tall, with carving. 2D Nording Freehand Apple, smooth. *FLAT Normally $100. Now only $59.95 Normally $200. Now only $110 (not shown) BOTTOM “SITTERS” 3A 3B 3H* TABLE OF CONTENTS Cigars . 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 bjarne Pipes . 31, 32, 33, 35, 36, 37, 38, 40, 40, 41, 48, 50 Cigarettes and Accessories . 16, 42, 43, 44, 46, 47, 48 3A Churchwarden with Carving. $65 Flasks and Barware . 49 3B Churchwarden Smooth. $79 Humidors . 10, 11 3C Bent Prince with Carving. $65 Lighters. 15, 17, 39, 51 3D Freehand Sitter with Carving.
    [Show full text]
  • Heated Cigarettes: How States Can Avoid Getting Burned
    HEATED CIGARETTES: HOW STATES CAN AVOID GETTING BURNED 8/30/18 1 HEATED CIGARETTES HOW STATES CAN AVOID GETTING BURNED 8/30/18 2 THE PUBLIC HEALTH LAW CENTER 8/30/18 3 8/30/18 4 LEGAL TECHNICAL ASSISTANCE Legal Research Policy Development, Implementation, Defense Publications Trainings Direct Representation Lobby 8/30/18 5 HEATED CIGARETTES HOW STATES CAN AVOID GETTING BURNED • Presenters: – Kristy Marynak, MPP, Public Health Analyst, Centers for Disease Control and Prevention – Hudson Kingston, JD, LLM, Staff Attorney, Tobacco Control Legal Consortium at the Public Health Law Center 8/30/18 6 HEATED CIGARETTES HOW STATES CAN AVOID GETTING BURNED • Heated cigarettes on the global market • Distinguishing features 1. Heating at a temperature lower than conventional cigarettes that produce an inhalable aerosol • Heated Cigarettes: 450-700° F (generally) • Conventional cigarettes: 1250 – 1300 °F, • (max: 1500 °F) 2. Processed, commercial tobacco leaf is the nicotine source, flavor source, or both 8/30/18 7 HEATED CIGARETTES HOW STATES CAN AVOID GETTING BURNED Federal Regulation • Pre-Market Review • Modified Risk Tobacco Product Application • Vapeleaf 8/30/18 8 Heated Tobacco Products: Considerations for Public Health Policy and Practice KRISTY MARYNAK, MPP LEAD PUBLIC HEALTH ANALYST CDC OFFICE ON SMOKING AND HEALTH TOBACCO CONTROL LEGAL CONSORTIUM WEBINAR AUGUST 2018 8/30/18 9 What’s the public health importance of this topic? The landscape of tobacco products is continually changing By being proactive and anticipating new products, we can
    [Show full text]
  • Altria Group, Inc. Annual Report
    Altria Group, Inc. 2019 Annual Report an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company an Altria Company Howard A. Willard III Dear Fellow Shareholders Chairman of the Board and CEO Altria delivered solid performance in a dynamic year for the tobacco industry. Our core tobacco businesses delivered outstanding financial performance, and we made significant progress advancing our non-combustible product platform. We believe Altria’s enhanced business platform positions us well for future success. 2019 Highlights n Grew adjusted diluted earnings per share (EPS) by 5.8%, primarily driven by our core tobacco businesses; and types of legal cases pending against it, especially during the fourth n Achieved $600 million in annualized cost savings, exceeding our $575 quarter of the year. Altria recorded two impairment charges of our JUUL million target announced in December 2018; asset in 2019, reducing our investment to $4.2 billion at year-end, down from n Increased our regular quarterly dividend for the 54th time in 50 years $12.8 billion, our 2019 initial investment. JUUL remains the U.S. leader in the and paid shareholders approximately $6.1 billion in dividends; and e-vapor category, and in January 2020 we revised certain terms governing n Repurchased 16.5 million Altria shares for a total cost of $845 million.
    [Show full text]
  • Robert K. Jackler Testimony.Pdf
    Brief Biography of Robert K. Jackler, MD: Dr. Jackler is a professor at the Stanford University School of Medicine and is a practicing surgeon. He is the founder and principal investigator of an interdisciplinary research group (Stanford Research Into The Impact of Tobacco Advertising or SRITA) which conducts research into the promotional activities of the tobacco industry. SRITA collected 56,600 original tobacco advertisements which were donated to the National Museum of American History of the Smithsonian Institution. A public exhibit at NMAH drawn from this collection opened in April 2019. SRITA maintains an extensive online tobacco advertising research database (tobacco.stanford.edu) which has over 813,000 unique users. As an academic research program, SRITA scholars conduct a wide spectrum of research into the promotional behaviors of the tobacco industry. SRITA focuses upon original scholarship utilizing the unique resource of our advertising collection. Our early academic focus was primarily an historical study of advertisements from the 20th century. In recent years, our research has focused upon the design and marketing of emerging tobacco products such as e-cigarettes (e.g. JUUL), heated tobacco (e.g. IQOS), and novel nicotine delivery systems. Our research is primarily designed to provide scientific data and analysis to inform regulators and legislators. SYNOPSIS OF OPINIONS: Today’s Tobacco Advertising Conveys the Same Messages as it Did in the 1950s: I suspect that most Americans think that the worst excesses of tobacco marketing lay in the 20th century when countless ads glorified smoking as glamorous and sexy and a worried public was reassured that “More Doctors Smoke Camels.” While the tobacco industry loudly claims they advertise ethically today, my in-depth study of tobacco advertising makes it clear that they still convey the same messages as during the earlier era.
    [Show full text]
  • Directory for Cigarettes and Roll-Your-Own Tobacco
    DEPARTMENT OF THE ATTORNEY GENERAL STATE OF HAWAI‘I DIRECTORY FOR CIGARETTES AND ROLL-YOUR-OWN TOBACCO of (Available at: http://ag.hawaii.gov/cjd/tobacco-enforcement-unit/) Certified Tobacco Product Manufacturers Their Brands and Brand Families DEPARTMENT OF THE ATTORNEY GENERAL TOBACCO ENFORCEMENT UNIT 425 QUEEN STREET HONOLULU, HAWAI‘I 96813 (808) 586-1203 INDEX I. Directory: Cigarettes and Roll-Your-Own Tobacco Page 1. INTRODUCTION 3 2. DEFINITIONS 3 3. NOTICES 5 II. Update Summary For September 22, 2017 Posting III. Alphabetical Brand List IV. Compliant Participating Manufacturers List V. Compliant Non-Participating Manufacturers List Posted: September 22, 2017 2 1. INTRODUCTION Pursuant to Haw. Rev. Stat. §245-22.5(a), beginning December 1, 2003, it shall be unlawful for an entity (1) to affix a stamp to a package or other container of cigarettes belonging to a tobacco product manufacturer or brand family not included in this directory, or (2) to import, sell, offer, keep, store, acquire, transport, distribute, receive, or possess for sale or distribution cigarettes1 belonging to a tobacco product manufacturer or brand family not included in this directory. Pursuant to §245-22.5(b), any entity that knowingly violates subsection (a) shall be guilty of a class C felony. Pursuant to Haw. Rev. Stat. §§245-40 and 245-41, any cigarettes unlawfully possessed, kept, stored, acquired, transported, or sold in violation of Haw. Rev. Stat. §245-22.5 may be ordered forfeited pursuant to Haw. Rev. Stat., Chapter 712A. In addition, the attorney general may apply for a temporary or permanent injunction restraining any person from violating or continuing to violate Haw.
    [Show full text]
  • Altria Group, Inc. Annual Report
    ananan Altria Altria Altria Company Company Company an Altria Company ananan Altria Altria Altria Company Company Company | Inc. Altria Group, Report 2020 Annual an Altria Company From tobacco company To tobacco harm reduction company ananan Altria Altria Altria Company Company Company an Altria Company ananan Altria Altria Altria Company Company Company an Altria Company Altria Group, Inc. Altria Group, Inc. | 6601 W. Broad Street | Richmond, VA 23230-1723 | altria.com 2020 Annual Report Altria 2020 Annual Report | Andra Design Studio | Tuesday, February 2, 2021 9:00am Altria 2020 Annual Report | Andra Design Studio | Tuesday, February 2, 2021 9:00am Dear Fellow Shareholders March 11, 2021 Altria delivered outstanding results in 2020 and made steady progress toward our 10-Year Vision (Vision) despite the many challenges we faced. Our tobacco businesses were resilient and our employees rose to the challenge together to navigate the COVID-19 pandemic, political and social unrest, and an uncertain economic outlook. Altria’s full-year adjusted diluted earnings per share (EPS) grew 3.6% driven primarily by strong performance of our tobacco businesses, and we increased our dividend for the 55th time in 51 years. Moving Beyond Smoking: Progress Toward Our 10-Year Vision Building on our long history of industry leadership, our Vision is to responsibly lead the transition of adult smokers to a non-combustible future. Altria is Moving Beyond Smoking and leading the way by taking actions to transition millions to potentially less harmful choices — a substantial opportunity for adult tobacco consumers 21+, Altria’s businesses, and society. To achieve our Vision, we are building a deep understanding of evolving adult tobacco consumer preferences, expanding awareness and availability of our non-combustible portfolio, and, when authorized by FDA, educating adult smokers about the benefits of switching to alternative products.
    [Show full text]
  • Temporary Compliance Waiver Notice the Linked Files May Not Be Fully Accessible to Readers Using Assistive Technology
    Temporary Compliance Waiver Notice The linked files may not be fully accessible to readers using assistive technology. We regret any inconvenience that this may cause our readers. In the event you are unable to read the documents or portions thereof, please email [email protected] or call 1-877-287-1373. Philip Morris Products S.A. THS Page 1 PMI Research & Development 2.7 Executive Summary MRTPA Section 2.7 Executive Summary Confidentiality Statement Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International. Philip Morris Products S.A. THS Page 2 PMI Research & Development 2.7 Executive Summary TABLE OF CONTENTS 2.7.1 EXECUTIVE SUMMARY .....................................................................................9 2.7.2 PROPOSED MODIFIED RISK AND MODIFIED EXPOSURE CLAIMS ........15 2.7.3 MODIFIED RISK TOBACCO PRODUCTS AND HARM REDUCTION .........17 2.7.4 PRODUCT DESCRIPTION AND SCIENTIFIC RATIONALE ..........................19 Development Rationale and Product Description for THS ............................................19 Heating Instead of Burning Reduces Harmful Constituents ......................................19 Product Description ...................................................................................................20
    [Show full text]
  • July 16, 2018 VIA ELECTRONIC SUBMISSION and HAND DELIVERY Division of Dockets Management Food and Drug Administration 5630 Fishe
    Jose Luis Murillo Vice President Regulatory Affairs July 16, 2018 VIA ELECTRONIC SUBMISSION AND HAND DELIVERY Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-N-6189 (83 Fed. Reg. 11,818, March 16, 2018) Advance Notice of Proposed Rulemaking on Tobacco Product Standard for Nicotine Level of Certain Tobacco Products Altria Client Services (“ALCS”), on behalf of Philip Morris USA Inc. (“PM USA”), John Middleton Company (“JMC”), and Sherman Group Holdings LLC and its subsidiaries (“Nat Sherman”),1 submits these comments to the Food and Drug Administration’s (“FDA’s” or the “Agency’s”) Advance Notice of Proposed Rulemaking (“ANPRM”) on a Tobacco Product Standard for Nicotine Level of Certain Tobacco Products. The ANPRM comes within the context of an industry in the midst of transformative change. Cigarette smoking is at historically low levels and continues to decline. At the same time, a new market is emerging in innovative noncombustible tobacco products that are potentially less harmful than cigarettes. There is now a scientific consensus that noncombustible products, like e-vapor, are substantially less risky than conventional cigarettes. It is smoke, and not nicotine, that causes most tobacco- related harm. And adult smokers are increasingly expressing interest in switching from cigarettes to less risky alternatives. We agree that a nicotine product standard of some sort may make sense in a future regulatory system, but this requires the pre-existence of a marketplace with alternative, FDA-authorized, reduced risk products; more information about the relative risks of those products; and a regulatory system that respects the rights of adults to make decisions based on accurate information.
    [Show full text]
  • Heated Tobacco Products' Reduced Exposure Claims
    Research paper Tob Control: first published as 10.1136/tobaccocontrol-2018-054324 on 12 September 2018. Downloaded from Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims Lucy Popova,1 Lauren Kass Lempert,2 Stanton A Glantz2,3 ► Additional material is ABStract As of February 2018, the new HTPs, like PMI’s published online only. To view Introduction Heated tobacco products (HTPs) are IQOS, were being sold in multiple countries around please visit the journal online being marketed in several countries around the world the world in minimalist high-tech looking stores (http:// dx. doi. org/ 10. 1136/ 5–7 tobaccocontrol- 2018- 054324). with claims that they are less harmful than combusted that resemble Apple stores. Advertisements and cigarettes, based on assertions that they expose users marketing materials for IQOS emphasise both its 1School of Public Health, to lower levels of toxicants. In the USA, Philip Morris superiority over combustible cigarettes (in terms Georgia State University, International (PMI) has submitted an application to the of cleanliness and customisability) and similarity Atlanta, Georgia, USA 2Center for Tobacco Control Food and Drug Administration (FDA) in 2016 seeking to them (in terms of product’s taste, size and 6 Research & Education, authorisation to market its HTPs, IQOS, with reduced risk providing similar behavioural experience). Claims University of California, San and reduced exposure claims. about health benefits or lower risks of IQOS are not Francisco, California, USA Methods We examined the PMI’s Perception and emphasised in the marketing materials and some of 3Department of Medicine, Cardiovascular Research Behavior Assessment Studies evaluating perceptions of the materials carry minimal health warnings, such Institute, Philip R.
    [Show full text]
  • PMI Powerpoint Presentation
    Investor Day – Asia Region Lausanne, June 23, 2010 Matteo Pellegrini President, Asia Region Philip Morris International Agenda ● Operating environment ● PMI strategic priorities in Asia ● Brand portfolio and innovations ● Key Asia markets: highlights ● Questions & Answers 2 Operating Environment 2009 • Population : 3.8 billion Korea Japan • Cigarette Volume: 3.4 trillion China Taiwan Cigarette Volume: Pakistan Hong Kong 1.2 trillion units (Excl. – China) Others 15% India Bangladesh Indonesia Thailand Philippines 22% Vietnam Bangladesh 6% Malaysia Pakistan Singapore 6% Vietnam Indonesia 7% Japan 20% Australia Philippines New Zealand 7% Korea 8% India Asia accounts for 56% of the world’s population 9% And 60% of the world’s cigarette volume… Note: Cigarette volumes reflect 2009 Source: Global Insights 3 GDP Per Capita in 15 Key Markets ($ 000) 50 43.9 39.9 36.4 30.4 USA US $ 46,300 European Union US $ 33,100 Asia Pacific US $ 4,000 17.2 16.5 7.0 Asia: $ 4.0 3.9 3.5 2.3 1.8 1.1 1.0 0.9 0.6 0 India China Japan Taiwan Vietnam Thailand Pakistan Malaysia Australia Indonesia Singapore Philippines Hong Kong Bangladesh South Korea Source: Global Insights 4 GDP Growth and Unemployment Rates (%) Japan (%) Australia 7 7 7 7 5.1 4.7 4.1 5.6 3.8 4.0 5.2 4.8 4.4 2.0 2.3 2.0 4.2 2008 2009 4.7 3.3 0 0 2.6 2006 2007 2010 F 2.4 (1.2) 1.3 (5.2) (7) (7) 0 0 GDP Growth Rate 2006 2007 2008 2009 2010 F Unemployment Rate (%) Indonesia (%) Philippines 12 12 12 12 10.3 9.1 8.4 7.9 8.1 8.0 7.3 7.4 7.5 7.3 6.3 6.1 5.5 5.6 5.3 7.1 4.5 3.8 4.2 0.9 0 0 0 0 2006 2007 2008
    [Show full text]
  • Unmanufactured Tobacco, Burley
    Foreign Agricultural Service GAIN Report Global Agriculture Information Network Voluntary Report - public distribution Date: 11/30/2000 GAIN Report #PO0032 Portugal Tobacco and Products Annual 2000 Approved by: Robert Wicks U.S. Embassy, Madrid Prepared by: Leonor Ramos Report Highlights: Portuguese 2000 tobacco output is to remain at 6,193 Mt, farm weight basis, and in 2001 at forecast 6,111 Mt. A boosted industrial activity is to lead to an expansion of 2000 total un-manufactured tobacco imports up to estimated 15,000 Mt, and of 2001 imports up to forecast 17,000 Mt. Tobacco imports from the U.S. are to reach estimated 7,500 Mt in 2000, and forecast 8,100 Mt in 2001. 1 USD = 236 Pte. Includes PSD changes: Yes Includes Trade Matrix: Yes Unscheduled Report Madrid [SP1], PO GAIN Report #PO0032 TABLE OF CONTENTS Executive Summary .....................................................1 Commodity Name: Unmanufactured Tobacco, Total ..................................2 Production, Supply & Distribution Table .....................................2 Production ............................................................2 Consumption ..........................................................3 Trade .................................................................4 Policy ................................................................7 Production Quotas .................................................7 Prices and Subsidies ................................................8 Marketing .............................................................9
    [Show full text]
  • Cigarettes and Tobacco Products Removed from the California Tobacco Directory by Brand
    Cigarettes and Tobacco Products Removed From The California Tobacco Directory by Brand Brand Manufacturer Date Comments Removed #117 - RYO National Tobacco Company 10/21/2011 5/6/05 Man. Change from RBJ to National Tobacco Company 10/20's (ten-twenty's) M/s Dhanraj International 2/6/2012 2/2/05 Man. Name change from Dhanraj Imports, Inc. 10/20's (ten-twenty's) - RYO M/s Dhanraj International 2/6/2012 1st Choice R.J. Reynolds Tobacco Company 5/3/2010 Removed 5/2/08; Reinstated 7/11/08 32 Degrees General Tobacco 2/28/2010 4 Aces - RYO Top Tobacco, LP 11/12/2010 A Touch of Clove Sherman 1400 Broadway N.Y.C. Inc. 9/25/2009 AB Rimboche' - RYO Daughters & Ryan, Inc. 6/18/2010 Ace King Maker Marketing 5/21/2020 All American Value Philip Morris, USA 5/5/2006 All Star Liberty Brands, LLC 5/5/2006 Alpine Philip Morris, USA 8/14/2013 Removed 5/4/07; Reinstated 5/8/09 Always Save Liberty Brands, LLC 5/4/2007 American R.J. Reynolds Tobacco Company 5/6/2005 American Bison Wind River Tobacco Company, LLC 9/22/2015 American Blend Mac Baren Tobacco Company 5/4/2007 American Harvest Sandia Tobacco Manufacturers, Inc. 8/31/2016 American Harvest - RYO Truth & Liberty Manufacturing 8/2/2016 American Liberty Les Tabacs Spokan 5/12/2006 Amphora - RYO Top Tobacco, LP 11/18/2011 Andron's Passion VCT 5/4/2007 Andron's Passion VCT 5/4/2007 Arango Sportsman - RYO Daughters & Ryan, Inc. 6/18/2010 Arbo - RYO VCT 5/4/2007 Ashford Von Eicken Group 5/8/2009 Ashford - RYO Von Eicken Group 12/23/2011 Athey (Old Timer's) Daughters & Ryan, Inc.
    [Show full text]